Reuters: Novartis lung drug not inferior to GSK's Seretide, study shows

ZURICH (Reuters) - Patients taking Novartis' inhaled medicine Onbrez Breezhaler for chronic lung disease had benefits similar to those taking GlaxoSmithKline's Seretide, the Swiss drugmaker said on Friday, citing a late stage study. [Category: healthNews] http://feeds.reuters.com/~r/reuters/healthNews/~3/YUkEehf98dg/story01.htm

Read More